PMI's IQOS and cigarette ads in Israel.

Dec.15.2022
PMI's IQOS and cigarette ads in Israel.
Philip Morris International (PMI) used legal loopholes to market smoking products to Orthodox Jewish communities in Israel.

The leading global tobacco company Philip Morris International (PMI) has taken advantage of a legal loophole in Israel's ban on advertising smoking products, targeting the extremely conservative Orthodox (Haredi) community in Israel through advertising campaigns, thus promoting smoking addiction among the residents of that region.


A new study led by Israeli doctoral student Amal Khayat and co-authored by Yael Bar-Zeev and researchers from the Braun School of Public Health and Community Medicine at Hebrew University in Israel was recently published in the academic journal "Tobacco Control". Titled "IQOS by PMI and cigarette advertising in the Israeli media: a content analysis across regulatory periods and target audience segments", the study examines the content of tobacco advertisements in Israel targeting specific groups of consumers.


Researchers analyzed marketing data from PMI to study the differences in advertising expenditures among several major population groups in Israel over the past four years, including the general population, Haredi communities, Arabic speakers, and Russian speakers.


Khayat stated, "In light of regulatory changes restricting tobacco product advertising, we have analyzed advertising expenditures for all PMI cigarette brands and IQOS brand (a heated tobacco stick introduced to the local market in December 2016).


Although restrictions on tobacco product advertising led to a significant decrease in the company's marketing expenditures, research shows that the company has been using legal loopholes in printing machines to subvert targets and maximize profits as much as possible.


Dr. Bar-Zeev explained that despite the law coming into effect, the company continued to spend nearly 3 million New Shekels on advertising, with a focus on print media. Although the law restricts print ads to one per newspaper, 40% of IQOS ads were huge double-page spreads that effectively doubled the advertising space for the product, while still being considered a single allowable ad under the law.


Another strategy utilized by PMI is to include QR codes in their advertisements, which allows readers to scan and view additional content outside of what is printed in the newspaper.


Furthermore, the advertisement shows individuals using IQOS devices to smoke in enclosed public spaces, despite laws prohibiting the use of any tobacco products in these areas. According to researchers, such ads give the impression that this behavior is legal, thereby taking advantage of the innocence of most consumers who may not be aware of these distinctions.


The study also found that prior to the enactment of this law, PMI significantly increased their advertising towards all reviewed populations, with a particular focus on the Haredi community, who had the lowest smoking rates in Israel before being targeted with PMI's marketing tactics.


According to Bar-Zeev, "Our data indicates that since introducing IQOS electronic cigarettes, 216 targeted advertisements have been released, of which 55% were created for the ultra-Orthodox community, 6% were created for the Arab public, and the rest were created for Russian-speaking audiences.


Similarly, 87% of cigarette ads are targeted towards the Haredi community, which is a surprising discovery as the company repeatedly claims to only be interested in marketing its products to existing smokers.


Bar-Zeev stated that the company is expected to focus on the population with the highest smoking rates in Israel - Arab males - rather than a population with almost no smokers.


According to research findings, Israel's 24th parliament has decided to cancel the exemption for print media advertising, but has ultimately postponed the implementation of this step for seven years. During the discussion, a series of additional restrictions were decided upon for this transition period, including the prohibition of using coupons, QR codes, and cigarette packaging that does not include mandatory plain packaging in print ads.


Bar-Zeev concluded that the restrictions were only a drop in the bucket because the study proved that tobacco companies found creative ways to continue marketing their products and addicting new generations despite the limitations. The researchers suggested that only a complete and immediate ban on all forms of advertisement, along with strict enforcement, could prevent such a scenario from happening.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10